Travere Therapeutics, Inc. Income Statement

Income Statement Feb2011 Feb2012 Dec2012 Dec2013 Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.08M-0.05M28.20M99.89M133.59M154.94M164.25M175.34M198.32M12.00M109.46M145.24M233.18M
Cost of Revenue 0.57M2.19M4.55M3.60M5.53M5.23M6.13M3.82M4.42M11.45M7.74M
Gross Profit -0.08M-0.05M27.63M97.71M129.04M151.33M158.72M170.10M192.19M8.18M105.04M133.79M225.43M
Operating items
Amortization - Intangibles 0.01M
Research & Development 0.66M1.04M47.80M50.43M70.82M78.17M123.76M140.96M131.77M201.16M227.33M244.99M217.50M
Selling, General & Administrative 0.01M0.01M29.59M17.69M59.65M79.54M91.94M101.33M103.65M128.95M135.80M126.28M197.52M265.54M264.12M
Restructuring Costs 5.21M3.61M-0.24M11.39M2.44M
Other Operating Expenses 0.01M0.00M-0.10M6.05M0.57M15.50M23.83M25.62M17.12M42.78M106.91M3.82M4.42M11.45M72.95M
Operating Expenses 0.02M0.01M30.26M24.77M108.01M150.64M191.81M208.73M244.29M312.70M374.48M331.26M429.27M533.38M557.00M
Operating Income -30.26M-24.77M-79.81M-50.75M-58.21M-53.79M-80.04M-137.36M-176.16M-199.43M-319.81M-388.14M-323.83M
EBIT -0.02M-0.01M-30.26M-24.77M-79.81M-50.75M-58.21M-53.79M-80.04M-137.36M-176.16M-199.43M-319.81M-388.14M-323.83M
Non-operating items
Interest & Investment Income 0.02M-0.05M-7.43M-7.75M-0.76M3.23M5.50M-18.83M-19.05M-19.68M6.28M21.77M17.82M
Other Non Operating Income -0.09M0.37M2.35M-4.15M-0.26M1.11M-17.04M-0.31M1.42M0.23M-7.60M1.59M-3.32M
Non Operating Income -0.09M-9.78M-33.59M156.22M0.63M-4.57M-21.83M-9.09M-12.63M-17.46M-11.34M12.03M-3.32M
Net income details
EBT -0.02M-0.01M-30.34M-34.55M-113.40M105.47M-57.58M-58.36M-101.87M-146.45M-188.79M-216.88M-331.15M-376.11M-320.51M
Tax Provisions 0.08M-2.46M-11.77M-9.68M1.37M0.81M-0.02M-19.36M0.41M0.31M0.22M0.12M
Profit After Tax -0.02M-0.01M-30.34M-34.62M-110.94M117.24M-47.90M-59.73M-102.68M-146.43M-169.43M-217.29M-331.47M-376.33M-321.55M
Income from Continuing Operations -0.02M-0.01M-30.34M-34.62M-110.94M117.24M-47.90M-59.73M-102.68M-146.43M-169.43M-217.29M-331.47M-376.33M-320.63M
Consolidated Net Income -0.02M-0.01M-30.34M-34.62M-110.94M117.24M-47.90M-59.73M-102.68M-146.43M-169.43M37.20M52.99M264.93M-0.92M
Income towards Parent Company -0.02M-0.01M-30.34M-34.62M-110.94M117.24M-47.90M-59.73M-102.68M-146.43M-169.43M37.20M52.99M264.93M-0.92M
Net Income towards Common Stockholders -0.02M-0.01M-30.34M-34.62M-110.94M117.24M-47.90M-59.73M-102.68M-146.43M-169.43M37.20M52.99M264.93M-0.92M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 12.07M18.38M26.70M36.15M37.73M39.31M41.25M42.96M51.05M61.23M64.17M75.15M78.05M
Shares Outstanding (Diluted Average) 14.21M25.06M37.58M38.29M38.77M40.43M42.34M47.54M59.83M63.76M74.27M78.89M
EBITDA -0.02M-0.01M-30.34M-34.73M-106.54M112.27M-47.71M-60.26M-103.19M-144.17M-171.06M-179.75M-280.83M-109.95M-320.17M
Tax Rate 2.17%16.81%0.01%10.25%